TRIP4 Exon 11 Deletion in 4 Related Patients: Expanding the Molecular Landscape of ASC-1 Complex–Related Neuromuscular Disease
Journal of Child Neurology · 20.11.2026
DOI: 10.1177/08830738261510104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Child Neurology, online erschienen am 20.11.2026. Verfasst von Murat Ozturk und 2 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Pathogenic variants in TRIP4 are a known cause of several congenital neuromuscular disorders, including spinal muscular atrophy with congenital bone fractures, congenital myopathy, and cerebellar hypoplasia with peripheral neuropathy. TRIP4 encodes a core component of the Activating Signal Cointegrator 1 (ASC-1) complex, but intragenic deletions affecting this gene have rarely been reported. Here, we describe 4 related individuals carrying a previously unreported homozygous deletion involving exon 11 of TRIP4 . Genetic testing was performed using next-generation sequencing, followed by confirmation with Sanger sequencing. Chromosomal microarray analysis independently confirmed the exon-level deletion and did not reveal additional pathogenic copy number variants. The same deletion was identified in all affected family members. Clinically, patients showed variable neuromuscular involvement within the same pedigree. In addition to neuromuscular involvement, affected individuals exhibited neurodevelopmental features, including delayed speech development, learning difficulties, and seizures, further expanding the clinical spectrum associated with TRIP4 deficiency. This variability is consistent with the broad phenotypic spectrum previously associated with ASC-1 complex dysfunction. To our knowledge, comparable familial cases with a homozygous TRIP4 exon 11 deletion have not been reported. The exon 11 deletion is likely to affect TRIP4 protein function and may influence transcriptional regulation during muscle development. Our findings add a new type of TRIP4 alteration to the existing literature and support the routine evaluation of copy number variants alongside sequencing-based approaches when investigating rare congenital neuromuscular disorders. This finding supports a role for TRIP4 and the ASC-1 complex in neuromuscular development.
Zitieren
APA
Ozturk, M., Oztepeli, R., & Arslan, C. B. (2026). TRIP4 Exon 11 Deletion in 4 Related Patients: Expanding the Molecular Landscape of ASC-1 Complex–Related Neuromuscular Disease. Journal of Child Neurology. https://doi.org/10.1177/08830738261510104
Vancouver
Ozturk M, Oztepeli R, Arslan CB. TRIP4 Exon 11 Deletion in 4 Related Patients: Expanding the Molecular Landscape of ASC-1 Complex–Related Neuromuscular Disease. Journal of Child Neurology. 2026. doi:10.1177/08830738261510104
BibTeX
@article{Ozturk2026,
author = {Ozturk, Murat and Oztepeli, Rohat and Arslan, Cahide Bulut},
title = {TRIP4 Exon 11 Deletion in 4 Related Patients: Expanding the Molecular Landscape of ASC-1 Complex–Related Neuromuscular Disease},
journal = {Journal of Child Neurology},
year = {2026},
doi = {10.1177/08830738261510104}
}
EUVIMED